The phase 3 trial compared Lilly's pill against insulin glargine in adults with type 2 diabetes at higher cardiovascular risk. Full results are in The Lancet.
Recap by typeshit. Full story at The Lancet.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
McGill researchers pooled data on 25,816 adults. Amycretin reached about 23.9% placebo-subtracted loss and retatrutide about 22.1%, though trials differed.
Researchers found women who had used hormonal birth control were more likely to go on to begin semaglutide than women who never had.
Loading…